Yiyun Tang

Strategies to Mitigate Breast-related Adverse Events in Patients with High-risk Biochemically Recurrent Prostate Cancer Receiving Enzalutamide Monotherapy: Perspectives and Challenges

Neal D. Shore, Stephen J. Freedland, Lisa G. Horvath, Joe M. O’Sullivan et autres

us, au, gb, it, be (code pays fourni par la source)

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial

Neal D. Shore, Martin Gleave, Ugo De Giorgi, Antti Rannikko et autres

us, ca, it, fi, au, dk, es, br (code pays fourni par la source)

Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points

Neal D. Shore, Ugo De Giorgi, Ronald Tutrone, James L. Bailen et autres

us, it, nl, sk, au, es, fr (code pays fourni par la source)

Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age

Neal D. Shore, Ugo De Giorgi, Matko Kalac, Yiyun Tang et autres

us, it, ca, nl, br (code pays fourni par la source)

Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide plus leuprolide (enza combo): EMBARK post hoc analysis

Stephen J. Freedland, Martin Gleave, U. De Giorgi, Antti Rannikko et autres

Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide monotherapy (enza mono): EMBARK post hoc analysis

Stephen J. Freedland, U. De Giorgi, Ronald Tutrone, Lawrence I. Karsh et autres

Post hoc analyses of Symptomatic Skeletal Events (SSEs) in Patients (pts) with non-metastatic hormone-sensitive prostate cancer (nmHSPC) in EMBARK and metastatic HSPC (mHSPC) in ARCHES treated with enzalutamide (ENZA)

A.S. Merseburger, A. Armstrong, Arun Azad, A. Stenzl et autres

Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer

Neal D. Shore, Murilo Luz, Ugo De Giorgi, Martin Gleave et autres

us, br, it, ca, kr, es, fi, au, gb, fr (code pays fourni par la source)

Research on the Path Innovation of Integrating Campus Red Culture into Ideological and Political Education for College Students from the Perspective of Current Hot Topics

Yu Sheng, Yiyun Tang, Xu Cheng

cn (code pays fourni par la source)

2461P Baseline (BL) features and metastasis-free survival (MFS) by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR): EMBARK post hoc analysis

Neal D. Shore, Swetha Sridharan, B. Venugopal, Antti Rannikko et autres

us, au, gb, fi, it (code pays fourni par la source)

LBA87 EMBARK: Overall survival with enzalutamide in biochemically recurrent prostate cancer

N.D. Shore, Murilo Luz, U. De Giorgi, Martin Gleave et autres

us, br, it, ca, kr, es, fi, au, gb, fr (code pays fourni par la source)

Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) monotherapy (mono): EMBARK post hoc analysis.

Stephen J. Freedland, Ugo De Giorgi, Ronald Tutrone, Lawrence I. Karsh et autres

us, it, es (code pays fourni par la source)